巨梁状-团块型肝细胞癌的CT与钆塞酸增强MRI影像表现比较
本研究回顾性纳入220例接受肝切除的单发初治HCC患者,比较MTM-HCC在CT与钆塞酸增强MRI上的影像表现及诊断效能。MTM-HCC与≥50%动脉期乏血供成分、瘤内动脉、动脉期瘤周强化及非光滑肿瘤边缘相关。Rhee标准在MRI和CT上诊断效能相似,且CT上Rhee标准为总生存的独立预后因素。
要点
- MTM-HCC在CT上可见动脉期乏血供成分、瘤内动脉、动脉期瘤周强化及坏死等MRI已报道征象。
- Rhee标准(≥50%乏血供成分+≥2项 ancillary 征象)可用于CT,诊断效能与MRI相似。
- 动脉期减影图像可显示细微动脉期高强化,有助于HCC诊断。
核心结论
- MTM-HCC的MRI诊断标准适用于CT,诊断效能和预后意义相似。
- Rhee标准在MRI的敏感度41%、特异度97%,在CT的敏感度31%、特异度94%。
- CT上Rhee标准是总生存的独立预后因素。
研究设计与样本
- 由两名阅片者独立进行组织病理学和影像学评估。
- 比较不同影像模态对MTM-HCC诊断标准的诊断效能。
关键影像表现/征象
- MTM-HCC与≥50%动脉期乏血供成分、瘤内动脉、动脉期瘤周强化及非光滑肿瘤边缘相关(CT和MRI,p<.05)。
- 动脉期乏血供成分在MRI减影图像上较CT或MRI上更少见。
- 非环状动脉期高强化和LR-5在MRI减影图像上较MRI上更常见(p<.05)。
- MTM-HCC在CT动脉期的肿瘤衰减更低(p=.01)。
诊断标准与关键数值
- Rhee标准定义为≥50%乏血供成分且≥2项辅助征象(瘤内动脉、动脉期瘤周强化、非光滑肿瘤边缘)。
- Rhee标准MRI敏感度41%、特异度97%;CT敏感度31%、特异度94%。
临床应用与阅片要点
- 可将MRI上验证的MTM-HCC诊断标准用于CT阅片,注意动脉期乏血供成分、瘤内动脉、瘤周强化和非光滑边缘。
- 动脉期减影图像有助于显示细微动脉期高强化,提高HCC诊断信心。
- CT动脉期肿瘤衰减较低提示MTM-HCC可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the imaging findings of macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) on CT and MRI, and examine their diagnostic performance and prognostic significance.
METHODS: We retrospectively enrolled 220 consecutive patients who underwent hepatic resection between June 2009 and December 2013 for single treatment-naïve HCC, who have preoperative CT and gadoxetic acid-enhanced MRI. Independent reviews of histopathology and imaging were performed by two reviewers. Previously reported imaging findings, LI-RADS category, and CT attenuation of MTM-HCC were investigated. The diagnostic performance of the MTM-HCC diagnostic criteria was compared across imaging modalities.
RESULTS: MTM-HCC was associated with ≥ 50% arterial phase hypovascular component, intratumoral artery, arterial phase peritumoral enhancement, and non-smooth tumor margin on CT and MRI (p < .05). Arterial phase hypovascular components were less commonly observed on MRI subtraction images than on CT or MRI, while non-rim arterial phase hyperenhancement and LR-5 were more commonly observed on MRI subtraction images than on MRI (p < .05). MTM-HCC showed lower tumor attenuation in the CT arterial phase (p = .01). Rhee's criteria, defined as ≥ 50% hypovascular component and ≥ 2 ancillary findings (intratumoral artery, arterial phase peritumoral enhancement, and non-smooth tumor margin), showed similar diagnostic performance for MRI (sensitivity, 41%; specificity, 97%) and CT (sensitivity, 31%; specificity, 94%). Rhee's criteria on CT were independent prognostic factors for overall survival.
CONCLUSION: The MRI diagnostic criteria for MTM-HCC are applicable on CT, showing similar diagnostic performance and prognostic significance. For MTM-HCC, arterial phase subtraction images can aid in the HCC diagnosis by depicting subtle arterial hypervascularity.
KEY POINTS: • MTM-HCC on CT demonstrated previously described MRI findings, including arterial phase hypovascular component, intratumoral artery, arterial phase peritumoral enhancement, and necrosis. • The MRI diagnostic criteria for MTM-HCC were also applicable to CT, showing comparable diagnostic performance and prognostic significance. • On arterial phase subtraction imaging, MTM-HCC more frequently demonstrated non-rim enhancement and LR-5 and less frequently LR-M than MRI arterial phase, which may aid in the diagnosis of HCC.
引用
- Cha, Choi, Park, et al. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI. Eur Radiol. 2022. PMID: 35999373. doi:10.1007/s00330-022-09105-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。